[Long-term therapy with a retard theophylline preparation].
The present study was conducted to investigate the therapeutic effect of long-term treatment with a slow-release theophylline preparation on the pulmonary functions FEV1 and peak exspiratory flow (PEF). A total of 908 patients took part in this open multicenter study. Treatment with the slow-release theophylline resulted in an increase of FEV1 and PEF of about 20% in asthma and between 11% and 14% in COPD. Apart from theophylline itself, the galenic nature of the slow-release formulation also contributed to the therapeutic effect.
Keller
A
A
Bömches
B
B
Kandt
D
D
D003692:Delayed-Action Preparations; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008134:Long-Term Care; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D013806:Theophylline / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D013806:Theophylline
Dauertherapie mit einem Theophyllin-Retardpräparat.